Trending:
News
-
17 October 2018
SQZ Biotech signs up to $1bn immuno-oncology deal with Roche
Cell therapy company SQZ Biotechnologies has expanded its deal worth up to $1bn with Roche for the development and commercialisation of immune-oncology products.
-
17 October 2018
Samsung BioLogics may face legal action for alleged accounting breach
South Korea-based biopharmaceutical company Samsung BioLogics is likely to face disciplinary measures due to alleged accounting breach.
-
17 October 2018
Roche reports sales growth as new drugs ease pressure from biosimilar competition
Swiss pharma company Roche reported 7% year on year increase in sales to CHF42.1bn ($42.5bn) in the first nine months of 2018 as newly launched drugs offset the impact of...
-
16 October 2018
AstraZeneca to continue UK investment freeze due to Brexit uncertainty
Anglo-Swedish biopharma company AstraZeneca’s non-executive chairman Leif Johansson has unveiled to French newspaper La Monde that the company will continue its freeze on manufacturing investments in Britain if uncertainty over...
-
16 October 2018
Immugenyx and Janssen to develop SLE model for drug development
Immugenyx has signed a collaboration agreement with Janssen Research & Development to develop an in-vivo platform that will aid in treating systemic lupus erythematosus (SLE).
-
16 October 2018
US FDA grants ODD to Lynparza for treatment of pancreatic cancer
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Lynparza (olaparib) to be used for the treatment of pancreatic cancer.
-
16 October 2018
Allele Biotechnology gets NIH grant to develop sepsis therapies
Allele Biotechnology and Pharmaceuticals has secured grant from the National Institutes of Health (NIH) unit National Institute of General Medical Sciences to develop nanoantibody (nAb) therapies for sepsis.
-
15 October 2018
Pain drug developer Adynxx agrees to merge with Alliqua Biomedical
Pain drug developer Adynxx has signed a definitive merger agreement under which its stockholders would become the majority owners of Alliqua’s outstanding common stock on a fully-diluted basis.
-
15 October 2018
AbbVie and Sandoz resolve Humira biosimilar patent dispute
AbbVie has resolved global intellectual property litigation with Novartis subsidiary Sandoz over proposed biosimilar Hyrimoz (adalimumab) for its reference medicine Humira (adalimumab).
-
15 October 2018
Otsuka expands digital medicines alliance with Proteus Digital
Otsuka Pharmaceutical has expanded its global collaboration agreement with Proteus Digital Health for advancing a portfolio of digital medicines and care models to help patients with severe mental illness.
